# EDGAR Filing Document

**Accession Number:** 0000748592
**File Stem:** 0001493152-26-012941
**Filing Date:** 2026-3
**Character Count:** 2566
**Document Hash:** 0e28e1ebf80fa0e84a99e2a6674930ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-012941.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001493152-26-012941

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ernexa Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0000748592
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 311103425
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1035 CAMBRIDGE STREET
- **STREET 2:** SUITE 18A
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** (617) 798-6700

**MAIL ADDRESS:**
- **STREET 1:** 10531 4S COMMONS DRIVE
- **STREET 2:** SUITE 166-550
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eterna Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20221017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brooklyn ImmunoTherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NTN BUZZTIME INC
- **DATE OF NAME CHANGE:** 20051230

**Ernexa Therapeutics Inc.**

**1035 Cambridge Street, Suite 18A**

**Cambridge, MA 02141**

March 26, 2026

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

---

| | |
|:---|:---|
| **RE:** | **Ernexa Therapeutics Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **File No. 333-294307** |

---

REQUEST FOR ACCELERATION OF EFFECTIVENESS

Requested Date: March 30, 2026

Requested Time: 4:30 pm, Eastern Time

Ladies and Gentlemen:

Ernexa Therapeutics Inc. (the "Company") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-294307), be accelerated pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it is declared and becomes effective at 4:30 pm Eastern Time on March 30, 2026, or as soon thereafter as possible.

Please contact our counsel, Steven Lipstein of Lucosky Brookman LLP at 732-395-4416 with any questions you may have regarding this request. In addition, the Company requests that you kindly notify Mr. Lipstein by telephone when this request for acceleration has been granted.

---

| |
|:---|
| Sincerely yours, |
| ERNEXA THERAPEUTICS INC. |
| */s/ Sanjeev Luther* |
| Sanjeev Luther |
| President, Chief Executive Officer and Director |

---